TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) has announced notable findings from a recent market research study that focused on the TAAT concept, brand image and product-user experience. The two-part market research study was conducted by Toronto-based market research firm Burak Jacobson Partners Inc. among smokers aged 21 years and older living in Ohio, Michigan, Illinois and Pennsylvania. Highlights of the study included more than half of the respondents stated that they definitely would or probably would purchase TAAT products, with more than 28% of those responding definitely would citing the retail price of the product. In addition, the study noted that the ability to purchase TAAT online was a significant factor creating interest in the innovative TAAT tobacco-free and nicotine-free alternative to traditional cigarettes. “Conducting this study among smokers aged 21+ in Ohio and neighboring states after launching the product in Q4 2020 enables us to make near-term business decisions based on a combination of practical and theoretical insights,” said TAAT CEO Setti Coscarella in the press release. “Based on how frequently TAAT is reordered by retailers in Ohio and purchased online by smokers aged 21+ across the country, we know there is continued interest. . . . However, we need far more information than that in order to intelligently plan our efforts to roll TAAT out on a larger scale. In this two-part consumer research study, we learned many things about how TAAT is perceived both as a brand and as a product in concept, in addition to how the user experience of TAAT is regarded among those who sampled it. The responses to this study reinforced our belief that TAAT has several competitive advantages in the USD $814 billion global tobacco industry, including the novel element of being nicotine free and tobacco free, an attractive price point compared to tobacco cigarettes, and the ability to purchase TAAT online. As we expand our market footprint in 2021, we intend to capitalize on these advantages to capture the interest of smokers aged 21+ and further establish TAAT as a better choice and a recognized brand name in the tobacco category.”
TAAT Lifestyle and Wellness has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth, Leveraging Market-Changing Synergy from PBI’s Ultra Shear Technology Nanoemulsions Platform
SOUTH EASTON, MA / April 14, 2021 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced it has finalized terms and executed a new letter of intent to purchase the assets of an internationally-based developer and supplier of organically natural, eco-friendly agrochemicals. This acquisition allows the Company to enter the agrochemical market with sought after alternatives to synthetic pesticides and fertilizers serving the rapidly growing sectors of organic and environmentally sustainable agricultural production worldwide. The parties expect to complete definitive documents and to simultaneously sign and close the transaction within four weeks. Subsequently, the Company expects to initiate a series of announcements regarding the acquired assets, global distributorship arrangements, UST enhancement of key products, purchase order receipts/product shipments, and the expected accretive financial impact of the acquisition.
Global population growth is driving increasing demands on food production. Simultaneously, the world is embracing an awakening to the imperatives of environmental sustainability. While demand is soaring for traditional production-boosting synthetic pesticides and fertilizers, these products are in turn being eclipsed by new generations of eco-friendly agrochemicals. New and old generations of agrochemicals face common challenges in getting oily (hydrophobic) active ingredients to become effectively absorbed and thus “bioavailable” within targeted plant species (whose biochemistry is mostly water-based). PBI’s Ultra Shear Technology™ (“UST™”) nanoemulsification platform, which can make oils effectively soluble in water, is a strategic “change agent” technology platform for this market sector, expected to enable more effective agrochemical dosing while reducing the quantities of expensive active ingredients required. Pesticides, used to control insects that damage crops and severely limit production, are projected to grow in worldwide sales from $84.5 billion in 2019 to $131 billion by 2023. Fertilizers, used to replenish soil with essential nutrients required for better crop growth and production, are expected to achieve global sales of approximately $232 billion by 2025.
Mr. Richard T. Schumacher, President and CEO of PBI, commented: “As previously announced, upon completion, this acquisition of assets will establish PBI with a portfolio of respected brand names in the eco-friendly agrochemicals market, with unique and effective proprietary formulations, advantageous manufacturer relationships, trademarks, intellectual property, registrations and licenses, and access to distributor and end-customer relationships worldwide. We expect these assets to be accretive, driving significant new revenues and profitability by Q4 2021 and substantially in 2022 and beyond.”
Mr. Schumacher continued: “While the acquired assets are expected to be dramatically impactful, we expect that our UST nanoemulsions technology platform will propel a major improvement in the economics and effectiveness of agrochemicals. We are looking forward to the opportunity to leverage the UST technology platform within a diverse line of next-generation, eco-friendly agrochemicals that fall into two of the hottest growth segments in agricultural production worldwide: organic foods and environmental sustainability.”
PBI’s Board Chairman, Mr. Jeffrey N. Peterson expanded on the strategic context of this acquisition: “PBI’s UST platform provides a unique and highly effective route for the creation of nanoemulsions with extremely low and consistent droplet sizes, which offer revolutionary improvements in more effective and economical products with improved sensory profiles, texture, appearance, stability, water solubility, and bioavailability. We expect these products to serve an amazing diversity of large commercial markets, from food and beverages, to cosmetics, nutraceuticals, pharmaceuticals, and now agriculture.”
Mr. Peterson continued: “We have previously announced initial relationships to open up pharmaceutical and hemp-derived product applications, as well as plans to bring PBI into the cosmetics and personal care products markets. This asset acquisition will quickly drive our penetration into the agrochemicals sector; importantly, it also includes products in the commercial, and retail cleaning/disinfection/healthcare arena as well. It is also expected to quickly extend into cosmetics and personal care products. While our overall strategy continues to focus on a licensing and equipment leasing/servicing business model for UST worldwide, this investment into direct participation and potential redefinition of terms of competition within an entire market sector is expected to demonstrate the strategic reach and destiny for our UST platform, which we can extend into many other major market opportunities as well.”
The letter of intent executed between the companies details the milestones that need to be met to complete the transaction, including the completion of all due diligence and acquisition financing.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is for the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
For more information about PBI and this press release, please click on the following website link:
A recent study conducted by a faculty member from the University of Georgia, in partnership with a team of researchers from the University of Southern California, has found that the daily consumption of beverages sweetened with sugar during adolescence damages performance on a memory and learning task during adulthood. The group of researchers demonstrated that changes in the bacteria found in the gut could be the key to the memory impairment caused by sugar.
High-sugar diets have also been associated with health effects such as heart disease and obesity as well as impaired memory function.
The research, published in “Translational Psychiatry,” has been released at a time when not much is known about how the excessive consumption of sugar during childhood influences brain development, particularly in a region that’s essential for memory and learning, known as the hippocampus. Given that children are the largest consumers of added sugar, the research couldn’t have come at a better time.
Using a rodent model, the researchers also discovered that when parabacteroides, which are bacteria, were enriched into the guts of animals that had never consumed sugar, similar memory deficits were observed. First author of the study and UGA College of Family and Consumer Sciences assistant professor Emily Noble explained that early-life sugar increased the levels of bacteria, noting that the higher the levels of bacteria were the worse the animals performed on a task. Noble added that they also discovered that the bacteria was enough to damage memory in a way similar to sugar and noted that it also damaged other types of memory functions as well.
A joint publication of the U.S. Departments of Health and Human Services and Agriculture, the Dietary Guidelines for Americans recommends that individuals should limit their intake of added sugars to less than 10% of calories daily.
However, data obtained from the CDC demonstrates that Americans aged between 9 and 18 years of age usually exceed the aforementioned limit, with the majority of the calories coming from beverages that have been sweetened by sugar.
The researchers fed young rats an 11% sugar solution, which is similar to the sugar-sweetened beverages that are commercially available. They then had the rats perform a memory task that was hippocampus dependent, which had been designed to measure episodic contextual memory. The researchers discovered that the rats that ingested sugar in their early life had an impaired ability to remember the context in which they’d seen a familiar object or differentiate whether an object was new to a particular context.
Noble noted that future research was required to better identify different pathways through which gut-brain signaling operates.
One technique that could possibly help researchers better understand how gut-brain signaling occurs, a technique that has been used extensively by Predictive Oncology (NASDAQ: POAI), is data analytics and using artificial intelligence. Predictive Oncology is leveraging this technique to increase the rate at which cancer treatments are personalized.
NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced the addition of perishable, refrigerated and frozen goods to its expanding repertoire of grocery items. According to the update, the company is enhancing product offerings at its one-stop shop for everything plant-based by adding high-quality fresh and frozen products by various brands including Beyond Meat, Impossible Foods, Miyokos, Follow Your Heart, Gardein, Tofurkey and Alpha Foods. The new items are now available to order in the “Frozen” and “Refrigerated” sections of the company’s United States’ e-commerce platform, with the products to be available for shipping to Canadian customers later this year. “Launching the new refrigerated and frozen product line is a natural and thrilling next step for PlantX,” said Julia Frank, PlantX CEO. “By adding such items, we are building on our efforts to create an online presence where customers can access a versatile range of high-quality products that meet their everyday needs.”
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
EV (electric vehicle) revenues amounted to $19.5 million in 2020, growing 600+ percent from $2.7 million in 2019
First sales of battery and charging systems also drove revenue in 2020 and are expected to continue growing this year following the acquisition of WAVE
New Chief Revenue Officer Kristen Helsel has a proven track record in growing revenues in the automotive and energy management industries and will play an instrumental role in driving the company’s growth, performance and strategy
Ideanomics (NASDAQ: IDEX), a global company focused on enabling the widespread adoption of commercial electric vehicles and associated energy consumption, finished 2020 with significant resources available to drive long-term growth plans and substantially higher EV revenue than in 2019, in spite of the pandemic.
In an earnings release conference call on March 31, the Ideanomics management revealed the full operating results for the year 2020 and provided selected business highlights and updates, including the company’s progress in its Mobility unit activities as a result of its Sales 2 Financing 2 Charging (S2F2C) business model gaining traction in the EV industry (https://ibn.fm/aXDDW).
According to the official financial results, the company’s total revenue for 2020 amounted to $26.8 million, growing sequentially quarter over quarter, demonstrating the growing strength of the Ideanomics model. Gross profit was $2.1 million, which represented a gross margin of 7.7 percent.
Ideanomics is currently generating revenue from its S2F2C business model, which includes three operating features:
Vehicle and Battery Sales – Medici, Treeletrik, Energica, and Solectrac cover the three market segments for the company
Financing, Leasing, and Insurance – Financial services to fleet customers, commission-based delivery, and origination-fee based revenue
Charging and Energy Services – Charging as a service, battery swap programs, and WAVE wireless charging
Most of the total revenue reported for 2020 came from EV operations – more specifically, $19.5 million compared to $2.7 million in 2019, marking an increase of more than 600 percent. In 2020, revenues also included the company’s first sales of battery and charging systems, a major part of the EV ecosystem and Ideanomics’ S2F2C model. Revenues from charging systems are expected to continue growing following the acquisition of inductive charging business WAVE in January 2021, which will be included in the company’s financial results as of the current quarter.
Other key highlights mentioned during the earnings conference call included the acquisition of cash flow positive Timios Holding Corp. under the company’s Capital division in January 2021, investments in leading electric tractor company Solectrac in October 2020 and a purchase agreement with MEG for 2,000 units of D1, a custom electric ride-hailing vehicle, in December 2020.
“We are very pleased with the transformation that took place this past year,” said CEO Alf Poor said. “Despite a year highlighted by COVID-19, we were able to build the groundwork for 2021 and beyond for Ideanomics and we are excited for what the future holds with our recent activity across the EV ecosystem and developments in EV charging infrastructure.”
To further drive its long-term growth, performance and strategy plans and align the activity of its revenue-generating departments, Ideanomics has appointed Kristen Helsel, a proven executive with 20+ years of experience, as Chief Revenue Officer. Throughout her career, Helsel has amassed significant experience growing new business around disruptive technologies by identifying new lucrative deals, while also delivering strong P&L results and combining financial and busines strategies with technical execution for short and long-term gains (https://ibn.fm/lYon2).
Helsel has a proven track record for growing revenues in the automotive and energy management industries and building and leading high-performing sales teams. She has extensive experience in the renewable energy and tech fields, as before joining Ideanomics, she was a partner for DKS Investments, acting as a consultant for organizations in markets such as solar energy and storage, EV charging, robotics, drones, and more. She was also named one of the “Electrifying 100: the 100 Most Influential People” in the EV industry by Automotive News.
Helsel voiced excitement for the new position and her future work to help accelerate the growth of Ideanomics and commercial EV adoption. “I was attracted by the company’s global vision and progress as a leader in the fast-growing commercial EV market, and I am looking forward to leading Ideanomics revenue development as the business continues to scale,” she said.
“We are excited to bring someone on board with experience at the intersection between automotive and energy that is essential to successful EV adoption. Kristen joins Ideanomics at an important time when we are poised for growth in all of our markets,” Poor explained.
The Ideanomics Mobility division is part of a global commercial EV market expected to reach $132.73 billion by 2022, growing at an impressive CAGR of 39.9% from the $34.7 billion value reported in 2018 (https://ibn.fm/icXmZ). Grand View Research projects the global EV charging infrastructure is also expected to grow exponentially, at a rate of 33.4%, to reach $144.97 billion in 2028. The growth of the EV industry is expected to be driven by an increasing interest and support from the public, as more people are looking for a clean alternative to fossil fuel-powered vehicles.
For more information, visit the company’s website at www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Wednesday, April 14th, 2021UncategorizedComments Off on $IDEX Releases 2020 Financial Results, Appoints Chief Revenue Officer to Help Drive Long-Term Growth
A new study conducted by a team of researchers from the Aalto University in Finland has found that the carbon footprint of raw materials acquired through recycling electric vehicle batteries is 38% less than that of virgin raw materials.
In order to reach this conclusion, the researchers used simulation-based life cycle to account for water and energy consumption as well as emissions in smelting, a hydrometallurgical recycling process. Generally, this technique loses various raw materials including lithium while new hydrometallurgical processes work by separating battery metals from waste through dissolution, which allows the minerals to be recovered. However, the process uses up high amounts of chemicals and energy and produces contaminated waste waters.
Despite these faults, the researchers encountered minor overall “side effects” when the battery minerals, in particular aluminum and copper, were recycled, and found that the treatment of mixed waste streams reduced the chemical consumption in leaching. However, they also found a few problem areas.
For instance, in a media statement, lead author of the paper Marja Rinne explained that the researchers noticed that the use of sodium hydroxide as a neutralizing chemical considerably increased the environmental load of their process. The study was published online on “Science Direct.”
Based on their results, Rinne and her colleague researchers suggest using simulation-based life cycle analyses before new techniques are implemented. They note, through their observations, that these evaluations are useful in helping determine how various parameters or choices influence the environmental effects of a process, making them an efficient tool for decision-making that can be used by both policymakers and the industry.
It should be noted that for accurate inventory analysis, process modeling and scenario analysis were carried out.
With the fast adoption of EVs expected to significantly increase the demand for battery metals such as cobalt, nickel and lithium, the researchers also believe that this is the time to develop other methods of recycling. This can be seen in the European Union’s projections, which show that by 2030, the area will be required to host 30 million electric vehicles. This is why the region proposes to recycle 70% of lithium and 95% of copper, nickel and cobalt from electric cars by the end of the decade.
In the brief, study co-author Mari Lundström noted that research on technological innovations and their different effects on the environment go hand in hand, explaining that companies and countries would have to find and use the most ecological and viable recycling processes as the need for recycling will increase significantly in the future.
Sadly, some mining operations contaminate nearby land and water bodies. However, programs such as the one in which Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) could work with the U.S. federal government to remediate mines which were decommissioned during the Cold War, can fix such contamination.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman and chief executive officer. “As a global medical leader in comprehensive and holistic approaches to cardiovascular disease and sleep disorders, she will be a valuable addition to our growing organization. Her wealth of experience and credibility as an award-winning physician and researcher will help inform other physicians about our breakthrough diagnostic and treatment technologies.”
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Splash Beverage Group Inc. (SBEV) Benefits From Strongest U.S. Distilled Spirits Growth Rate in 18 years
The North American liquor industry benefitted from a surge in revenue growth in 2020, in spite of widespread restaurant, bar closures
U.S. distilled spirits gross revenues rose by 7.7% last year, the biggest percentage increase in 18 years with sales of tequila rising by 17.4% YoY
Splash Beverage Group has benefitted from industry’s growth trends, seeing its quarterly sales growth soar nearly 10-fold between Q1-Q42020
Splash Beverage has looked to diversify its product portfolio to benefit from ‘off-premise’ sales, including through recent acquisition of ‘Copa Di Vino’
With restaurants and bars shut across much of the United States for the majority of 2020, it would be only natural to assume that the North American liquor industry would have suffered alongside it; a study carried out in 2018 showed that on-premise alcoholic sales in establishments such as bars or restaurants accounted for over a gargantuan $147 billion in sales or 53% of total US alcohol revenues (https://ibn.fm/XpR0i). However, the experience over the past 12 months has been anything but normal. Splash Beverage Group (OTCQB: SBEV), a holding company for a leading portfolio of beverage companies, has been one of the players confounding expectations, having reported cumulative sales of $2.975 million in 2020 – while simultaneously seeing quarterly sales rise nearly tenfold between the first and fourth quarter of the year (https://ibn.fm/Avxhb).
Though impressive, Splash Beverage Group’s strong results may not have come to fruition without the supportive underlying trends witnessed within the U.S. alcoholic beverage industry. The United States Distilled Spirits Council reported that U.S. distilled spirits gross revenues rose by 7.7 percent in 2020, the biggest percentage increase in 18 years and the biggest dollar increase on record (https://ibn.fm/lxJOd). Although restaurant and bar closures contributed to a decline in alcoholic beverage sales during the spring of 2020, monthly consumer spending data showed that a rebound in retail sales combined with a partial recovery in bar and restaurant beverage sales (assisted by several states changing liquor laws to allow them to sell take-away beverages) had driven overall sales higher by the summer (https://ibn.fm/vpTHE).
There was also a notable shift in the type of alcohol being demanding. Whereas the volume of cordials (i.e., liqueurs, amari, etc.) sold declined by 1.8% last year as bars purchased fewer mixers for their cocktails, sales of tequila and mezcal soared, with the alcohol sub-category seeing total sales rise by 17.4% in 2020. Splash Beverage was a particular beneficiary of the trend through increased sales of its SALT Naturally Flavored Tequila brand.
With social distancing regulations still in force across much of the nation, Splash Beverage has sought to increase its emphasis on off-premise channel initiatives as a way to boost revenues for the group. In addition to announcing that its SALT Naturally Flavored tequila had been approved by Walmart in August of last year (https://ibn.fm/SMmkN), Splash Beverage recently completed the acquisition of Copa Di Vino, the nation’s largest ‘wine by the glass’ manufacturer. The company boasts a retail distribution footprint amounting to over 13 thousand outlets across the country (https://ibn.fm/3BKnD).
“Due to the conditions of the current pandemic and social distancing, our primary focus remains on off-premise channel initiatives and we are enjoying growth here,” said Splash Beverage CEO Robert Nistico regarding the company’s recent strategic moves. “We anticipate as bars, restaurants and hotels begin to open, we will experience growth with our relationships in on premise channels.”
NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
AmpliTech Group (NASDAQ: AMPG, AMPGW), a designer, developer, and manufacturer of custom and standard state-of-the-art RF (“RF”) components for commercial, SATCOM, 5G, quantum computing, space, defense and military markets, has received a developmental order for its exclusive cryogenic probe head; the order was received from Amplify My Probe Ltd. The cryogenic device, which uses AmpliTech’s innovative cryogenic low-noise amplifier technology, is designed for use in the study of materials, molecules and drugs for the treatment of diseases. A spin out from the Quantum Spin Dynamics group at the London Centre for Nanotechnology and UCLQAmplify, My Probe commercializes technology to improve the signal-to-noise ratio in EPR experiments. The Amplify My Probe team noted that the device allows the measurements of the electron paramagnetic resonance (“EPR”) experiments to proceed much faster, an estimated 100x speed up of the experiments. The announcement noted that, among possible applications, the device could be used in studies of systems with the potential to design new drugs. The announcement also stated that AmpliTech Group will be the exclusive manufacturer for the cryogenice probe head while Amplify My Probe will be sole global distributor for at least the first 18 months. “We are pleased to work with the Amplify My Probe team to help develop this innovative new product that will advance materials science and medical technology,” said AmpliTech Group CEO Fawad Maqbool in the press release. “AmpliTech Group Inc. is dedicated to be a driving force and leader in amplifier technology for communications and microwave applications that are part of everyday life around us.”
AmpliTech Group designs, develops and manufactures custom and standard state-of-the-art RF components for the domestic and international, SATCOM, space, defense and military markets. These designs cover the frequency range from 50 kHz to 40 GHz – eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. The company’s steady growth over the past 13-plus years has come about because it can provide complex, custom solutions for nearly any custom requirements. In addition, AmpliTech Group has the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers’ own designs. For more information about the company, visit www.AmpliTechInc.com.
NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at http://ibn.fm/AMPG
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
XPhyto has just completed a rebranding effort that includes the launch of a new website
The company expects to begin launching other bacteria and virus diagnostic products later this year
With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response.
XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a Feb. 24 news release (https://ibn.fm/uBX94). The Covid-ID Lab is a rapid, point-of-care RT-PCR test system for COVID that the company expects to be useful for industry partners and licensees, as well as their respective government regulators, in safeguarding against the spread of the highly infectious and potentially fatal virus.
The first product order from 3a was for 9,600 tests, which are packaged in 200 kits of 48 tests each, according to the company. Delivery is expected this month and XPhyto anticipates they will then undergo evaluation by the company’s partners and the appropriate government agencies for expected commencement of sales in Q2 2021.
“We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” XPhyto CEO and Director Hugh Rogers stated in the news release. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.”
In March, XPhyto received two critical regulatory approvals in Europe to open the door for sales of its rapid, point-of-care COVID testing solution. On March 10, the company announced approval for commercial production under internationally agreed-on ISO 13485 quality standards (https://ibn.fm/qZCXm). On March 18, the company further announced Covid-ID Lab’s approval for in vitro diagnostic device (CE-IVD) use (https://ibn.fm/PqsZI).
On March 4, XPhyto announced completion of a corporate rebranding initiative that includes the launch of a new website.
“The company is excited to introduce a fresh look at such a pivotal point in our business growth,” Rogers added (https://ibn.fm/A4hzB).
XPhyto is on track to launch sales and distribution in Europe in April, and the company is also in talks with potential distribution and wholesale partners in the Middle East.
XPhyto intends to continue its rapid, point-of-care product development to target other pandemic-potential illnesses, such as H1N1 (swine flu) and H5N1 (avian flu), as well as a variety of other bacterial and viral infectious diseases. New products under an expanding portfolio could be launched before the end of the year.
XPhyto’s research and development operations are located in North America and Europe, but the company’s focus is the European market during these initial stages of product placement.
For more information on XPhyto Therapeutics, visit the company’s newly designed website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. The objective is for PH94B to displace these and other benzodiazepines, which are widely used but addictive, as a viable treatment for social anxiety disorder (“SAD”) and other anxiety disorders and phobias. SAD is the third most common mental health disorder among Americans, and recent studies indicate that an estimated 20 million individuals suffer with the debilitating disorder. “Given the FDA’s recent Drug Safety Communication that outlined and highlighted the safety risks associated with benzodiazepine use, the implications resulting from this study are significant,” said VistaGen chief medical officer Mark Smith, M.D., Ph.D., in the press release. “PH94B may have the potential to displace benzodiazepines altogether and become the safer alternative to help the millions of Americans suffering from anxiety with limited options for safe, effective treatment options. These existing treatments can actually hurt instead of help. We look forward to launching our Phase 3 clinical development program for PH94B next quarter and continuing to push forward in our mission to get it into the hands of those in need as soon as possible.”
VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
H.C. Wainwright and Co. increase price target, reiterate buy rating for UEC
Key moves by company lead to stronger position
UEC investing to build next generation of low-cost and environmentally friendly uranium projects that will be competitive on global basis, says CEO
Recent action taken by Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases, has prompted H.C. Wainwright and Co. to increase its price target for the company and reiterate its buy rating (https://ibn.fm/6wWpO). In its updated report, Wainwright specifically cited three main factors for the increase in price: UEC’s decision to obtain financing to support physical uranium purchases, the establishment of a physical uranium inventory initiative and the restart of wellfield development and definition drilling at the company’s Burke Hollow project.
“On March 22, Uranium Energy Corp. (‘UEC’) announced that it had closed an offering for total gross proceeds of $30.5M after issuing 10.0M common shares at a price of $3.05 per share,” the report stated. “These funds are expected to be used for additional uranium purchases, as well as general corporate and working capital requirements. . . . We highlight that UEC’s physical uranium initiative, which we discuss in more detail below, is fully funded with its current cash position, and now includes 1.4M pounds (lbs) of U.S. warehoused uranium.
“While the company remains focused on developing its low-cost, in-situ recovery (‘ISR’) mining capabilities, management has identified a unique opportunity to purchase drummed uranium at spot prices well below global industry mining costs,” the report continues. “As a result, UEC is establishing a physical uranium inventory initiative based on an initial agreement with ConverDyn in Illinois to acquire 0.4Mlbs of U.S. warehoused uranium for a total cost of $10.9M. . . . Management anticipates that this initiative can improve its balance sheet through uranium price appreciation and support future marketing efforts with utilities to accelerate cash flows. Looking ahead, this move should also increase the availability of Texas and Wyoming production capacity for emerging U.S. specific opportunities such as the U.S. Uranium Reserve (‘UR’).”
Finally, the H.S. Wainwright report stated that “on January 26, UEC announced that the company had commenced production area development at its Burke Hollow ISR project in Texas. We note that advancing and expanding resources is a critical step to supporting the company’s plan to participate in supplying the U.S. UR. The UR includes purchases of newly mined domestic uranium over a 10-year period for an aggregate value of $1.5B. Additionally, the FY21 bipartisan omnibus spending bill currently includes $75M for domestically produced uranium. We highlight that the U.S. Department of Energy is currently developing a plan to implement this program, which UEC expects to be a competitive bid process focused on existing fully permitted and low-cost projects.”
As a result of these key factors, H.C. Wainwright and Co. reiterated its buy rating on EUC shares while raising its price target to $5 from $3.60, a move worth noting by one of the country’s oldest and most-trusted financial institutions.
UEC is focused on establishing a stronghold in the growing U.S.-based uranium space. “With $65.8 million in cash and equity holdings, UEC has the balance sheet strength to lead U.S. uranium production higher at the most critical time for the domestic industry since the inception of the civilian nuclear power program began in the 1950s,” said UEC CEO and president Amir Adnani (https://ibn.fm/f3N4T). “As a leading pure-play American uranium company, UEC is investing to build the next generation of low-cost and environmentally friendly uranium projects that will be competitive on a global basis.”
Uranium Energy Corp. is a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. Founded in 2003, UEC is headquartered in Corpus Christi, Texas. Properties acquired by the company are primarily located within the United States, including Texas, New Mexico, Colorado, Arizona and Wyoming. In addition, the company is aggressively pursuing other key developmental targets. UEC is poised to be a next-generation uranium producer and is committed to providing low-cost, low-capital fuel for the country’s large electricity-generating nuclear fleet.
NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Last week, a Texas House committee voted in favor of a bill to expand the state’s medical cannabis program. One of a number of cannabis reform bills discussed by the legislature last week, the legislation was sponsored by House Public Health committee chair Stephanie Klick. The bill is designed to significantly expand Texas’ already-limited medical marijuana Compassionate Use Program (“TCUP”), adding a couple more conditions to the list of diseases that qualify patients for a medical marijuana prescription.
Patients suffering from chronic pain and any type of cancer, as well as veterans with post-traumatic stress disorder, will now be able to take medical marijuana to treat their conditions. Bill HB 1535 will also include debilitating conditions that have been determined by the Department of State Health Services and included on the list of qualifying conditions. On top of that, the legislation will increase the medical marijuana cap for THC (delta-9 tetrahydrocannabinol) from 0.5% to 5%.
Finally, House Bill 1535 would create institutional review boards and authorize those boards to promote studies on medical cannabis and how the state’s medical cannabis program has affected its patients. The 11-0 vote in favor of the legislation came after a landmark committee hearing that included testimonies from physicians, veterans and Texans who were forced to manage or treat their medical conditions with opioids.
Klick, who authored as well as sponsored it, is also responsible for separate legislation that expanded the state’s medical cannabis program to include seizure disorders, multiple sclerosis (“MS”) and terminal cancer in 2019. Klick says the new bill will expand the medical cannabis program again and task Texas Health and Human Services with creating a medical cannabis research program. The legislation has been met with plenty of support from medical cannabis patients, industry stakeholders and drug reform advocates.
According to Texas Original Compassionate Cultivation CEO Morris Denton, the bill is a step in the right direction. However, he concedes that it still isn’t as comprehensive as he would have liked it to be, and his opinion is shared by many. The hope was that the committee would amend the legislation to remove the cap for THC, allow all patients who can benefit from it to use medical cannabis, allow independent laboratories to test marijuana products, and grant physicians and patients in the medical cannabis space legal protections.
Despite this, Texans for Responsible Marijuana Policy isn’t worried. Its representatives as well as Senators will have the chance to make amendments to House Bill 1535 on the floor.
As the debate on the expansion of the medical cannabis bill rages on, there are cannabis products that are legal across the country. To access these products, consumers don’t need a physician’s recommendation. Such products include the CBD-infused tinctures, drinks, powder packs and gummies made by many companies, including The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER).
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
TAAT Lifestyle & Wellness (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) CEO Settie Coscarella is slated to present at the upcoming Investing in Innovation Global Chinese Financial Forum (“GCFF”). The online event is scheduled for Thursday, April 15; Coscarella’s 20-minute presentation will begin at 1:25 pm EDT and will include an explanation of TAAT’s unique position in the $814 billion global tobacco industry as well as company’s impressive progress since its launch last year. Coscarella will talk about the company’s U.S. product launch in Ohio and online as the company has focused on making the product available to the majority of smokers aged 21 and above in the United States. The GCFF series of events is produced by NAI Interactive Ltd. (“NAI”), a market intelligence and investor relations service provider founded in 1998 with offices in Vancouver and Shanghai; the events are designed to connect North American public companies with Chinese investors. Recent GCFF events include Diversified Investing Strategies, Base Metals & Energy Metals Day, and Precious Metals Day. “Now that we are establishing a presence in our initial market, we have a great story to share with a global audience of investors who may not yet be familiar with TAAT and its unique value proposition for smokers aged 21+,” said TAAT CEO Setti Coscarella in the press release. “The concept of a smokable product with no tobacco or nicotine is very novel, and it has attracted considerable interest from investors in China, whose population of tobacco smokers is approximately eight times the size of Canada’s total population. It has been a pleasure to work with NAI to create a presentation for the GCFF Investing in Innovationevent on Thursday, and I am looking forward to sharing our message with an eager and engaged audience of global investors as we continue to gain momentum with the launch of TAAT in the United States.”
TAAT Lifestyle and Wellness has developed TAAT, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in Original, Smooth and Menthol varieties. TAAT’s base material is Beyond Tobacco(TM), a proprietary blend that undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with Big Tobacco pedigree, TAAT was launched first in the United States in Q4 2020 as the company seeks to position itself in the $814 billion global tobacco industry. For more information, please visit www.TAATGlobal.com.
NOTE TO INVESTORS: The latest news and updates relating to TOBAF are available in the company’s newsroom at http://ibn.fm/TOBAF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,’ said Predictive Oncology CEO Dr. Carl Schwartz. ‘Furthermore, this project is a template we can use to partner with other health care institutions and expand our AI-driven clinical models to other cancers.’”
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced its appointment of Matthew Kenney, a leading plant-based chef, as its new chief culinary officer. Kenney will leverage his business acumen and vision for plant-based cuisine to revolutionize the culinary development at PlantX. His leadership role with PlantX will be facilitated through a new five-year partnership with MK Cuisine Global LLC (“MKC”), Kenney’s plant-based lifestyle brand. In addition, as detailed in the update, the company has entered into a non-binding letter of intent (“LOI”), dated April 12, 2021, pursuant to which PlantX proposes to acquire all of the outstanding limited liability membership interests of MKC’s Plant-Based Deli LLC (“New Deli”). “We are honored and humbled to have the godfather of vegan cuisine lead an important growth segment of PlantX,” said PlantX Founder, Sean Dollinger. “Matthew will provide invaluable wisdom that should give PlantX a competitive edge in the fast-growing plant-based space.” PlantX hosted a press conference at 10:30 a.m. ET today to discuss this collaboration, which is available for viewing at https://ibn.fm/vJJRI.
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Tuesday, April 13th, 2021UncategorizedComments Off on $PLTXF Announces Strategic Appointment of the ‘Godfather of Vegan Cuisine’ and Intended Acquisition
Just a few months into his first term, President Joe Biden has unveiled a massive infrastructure plan that would support a mass shift from fossil fuels to clean renewable energy and zero-emission vehicles. The Democrat campaigned on a green-energy platform, pledging to tackle the climate change crisis while simultaneously helping the country’s economy recover from the coronavirus pandemic. Soon after he assumed office, Biden announced a plan to build 500,000 public electric charging stations across the country.
The new infrastructure plan, which was released in late March, outlines his green-energy plan more conclusively. Among other things, the plan would support policies designed to boost electric vehicle (“EV”) adoption, provide funding for half a million public EV charging stations and prepare the electric grid for a mass shift from gas-powered vehicles to EVs. At the moment, EV adoption is held back by a variety of factors, chief among them the high upfront costs drivers have to bear as well as an insufficient and often unreliable network of public charging stations.
According to an official fact sheet released by the White House, Biden’s infrastructure plan sees technology leadership, climate change and more employment opportunities as connected issues that should be addressed together. The plan includes a massive $174 billion investment to boost EV adoption by supporting the retrofitting of factories, reducing reliance on foreign supply chains, boosting the local EV market, and providing job opportunities to develop EV batteries and electric vehicles.
The plan would provide tax incentives and point-of-sale rebates to make zero-emission vehicles more affordable as well as incentive programs and grants to support the development of a network of 500,000 EV chargers by 2030. The Biden administration has already pledged to replace its entire fleet of vehicles with EVs, prioritizing American-made models. The White House has also stated that one of its top priorities is expanding the tax credits EVs are already entitled to.
On top of electrifying the entire federal fleet, Biden’s infrastructure plan would see 50,000 gas-powered transit vehicles replaced with electric models. It would also provide funding for the electrification of 20% of America’s fleet of school buses. Finally, $15 billion has been designated for projects in carbon capture, utility-scale energy storage solutions and rare earth element separations, while $50 billion will be used to fortify the nation’s infrastructure against extreme weather events.
The electric vehicle industry is predictably happy with the infrastructure plan. Fred Krupp, president of the Environmental Defense Fund, notes that zero-emission electric buses and trucks are key to achieving the nation’s climate goals.
The federal infrastructure plan comes at just the time when the EV industry is waiting to see what the planned merger between Mullen Technologies and Net Element (NASDAQ: NETE) has to offer the electric vehicle sector that is evolving rapidly to meet motorists’ needs of today and years to come.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
HempFusion Wellness (TSX: CBD.U) (OTCQX: CBDHF) (FWB: 8OO), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, has provided a comprehensive operational update. Among the many highlights, the company announced that it ranks as second in the U.S. for CBD brand awareness according to the Brightfield Group and that, according to SPINS, Probulin Probiotics finished 2020 as the fastest-growing probiotic brand out of the top 10 in the U.S. “The company has built a strong foundation throughout a challenging 2020. After the completion of a successful IPO, the company remains focused on executing its five-channel strategy driving significant revenue growth across domestic and international markets in 2021 and beyond,” the update reads. “We remain hyper focused on the long game. The future is bright.”
HempFusion is a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition. HempFusion distributes its family of brands, including HempFusion, Probulin Probiotics, Biome Research, and HF Labs, to approximately 4,000 retail locations across all 50 states of the United States and select international locations. Built on a foundation of regulatory compliance and human safety, HempFusion’s diverse product portfolio comprises 48 SKUs including tinctures, proprietary FDA drug listed over-the-counter (“OTC”) topicals, doctor/practitioner lines and more. With a strong focus on research and development, HempFusion has an additional 30 products under development. HempFusion is a board member of the U.S. Hemp Roundtable, and HempFusion’s wholly-owned subsidiary, Probulin Probiotics, is one of the fastest-growing probiotics companies in the United States, according to SPINs reported data. HempFusion’s CBD products are based on a proprietary Whole Food Hemp Complex(TM) and are available in-store or by visiting HempFusion online at www.Hempfusion.com or www.Probulin.com.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at http://cnw.fm/HempFusion
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
The battery itself was the brainchild of an Italian more than 270 years ago, but it wasn’t until the 19th century that the idea was enhanced by a team of scientists.
Currently, the battery may be the key to the universal acceptance of the natural resources sector, especially if one considers the steadily increasing demand for metals out of which batteries can be made. As stated above, this big appetite is primarily driven by a widespread acceptance of an urgent need to decrease carbon emissions globally and the resulting manufacture of EVs.
The word “battery” was minted in 1749, during electricity experiments conducted by Benjamin Franklin. While it may not be commonly known, the person behind the invention of the battery was Alessandro Volta, an Italian who was the first to record the electrical phenomena in 1791 brought about by two different metals linked together using a moist electrolyte.
However, it wasn’t until 1800 that Volta thought up the first battery, comprised of zinc discs and copper kept separate by a brine-soaked cloth. Volta’s pile, as it was referred to, had several issues and was further improved in the 19th century.
The team of scientists —John Daniell, William Sturgeon and William Cruickshank— solved issues with the voltaic pile, including hydrogen bubbles, impurities within the zinc plus leaking electrolyte. But it wasn’t until 1837 that further improvements were made to the Daniell cell, as it had been christened by Golding Bird, a physician.
Bird went as far as to use the cell in London-based Guy’s Hospital. In 1839, William Grove, a Welshman, designed a cell that offered almost twice as much voltage as the Daniell cell did, using a platinum cathode inserted in a concentrated solution of nitric acid and a zinc anode in dilute sulfuric acid. This battery become so popular that it was used by the telegraph networks found in America between 1840 and 1860.
Nearly two centuries later, many analysts suspect that the emergence of electric cars will be significant to mining, especially now that the industry has a modern purpose and the increasing demand for these minerals will lead to direct investments in mining firms.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
A new study conducted by researchers from the University of Minnesota Medical School and their colleagues has found three phenotypes of the novel coronavirus, which demonstrate distinct characteristics as well as different clinical outcomes, complications and comorbidities in patient populations. The three COVID-19 phenotypes were discussed in detail in the researchers’ study, which was reported in the open-access “PLOS ONE” journal.
The coronavirus has infected more than 18 million individuals as well as led to the death of more than 700,000 people across the globe. The disease’s presentation varies considerably, which suggests that not only do distinct clinical phenotypes exist, but those phenotypes may also respond to treatment differently.
The researchers examined electronic health records obtained from 60 primary care clinics from the state of Minnesota and 14 healthcare facilities in the mid-western United States. They went through the records of 7,538 patients who had tested positive for the coronavirus between March 7 and August 25 last year. Of these patients, 1,022 of them needed hospital admission and took part in the study.
The data on each patient included their demographics, hospital admission information, clinic visits, lab values, medications and comorbidities.
The majority of the patients who were included in the study — about 60% of them — presented with the phenotype II, as christened by the researchers, while 23.2% of the remainder, which equates to 236 patients, presented with adverse phenotype, as dubbed by the researchers, which they also referred to as phenotype I. The latter was associated with the worst clinical outcomes, with researchers discovering that patients who presented with phenotype I were more likely to be non-English-speaking and non-White as well as having the highest level of cardiac, renal and hematologic comorbidities.
The remaining 16.9% of patients — 173 in total — presented with the favorable phenotype, or phenotype III, as dubbed by researchers. This phenotype was linked to the best clinical outcomes. However, while this phenotype had the lowest mortality and complication rates, patients who presented with phenotype III had a greater risk of hospital readmission, in comparison with the other phenotypes, in addition to having the highest rate of respiratory comorbidities. In general, phenotypes II and I were linked to increases in hazard of death, in comparison with phenotype III.
The study, whose first authors were Nicholas Ingraham and Elizabeth Lusczek, concluded that medical care that was phenotype-specific could improve coronavirus infection outcomes and suggested that further research would be needed in order to determine the usefulness of the findings in actual clinical practice.
The progress seen in understanding how the coronavirus affects different people is a result of the immense resources channeled to studying this novel condition, and parallels can be drawn with the way progress is being made in seeking better therapies for brain cancer sufferers by companies such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP).
NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Distribution of neurologists across the U.S. is uneven with 20 states experiencing neurology deserts
Brain Scientific has developed tools that help providers in neurology deserts provide access to neurological care
With explosion of telemedicine services and increased integration of advanced practice providers, neurologists’ shortage may improve
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is directly tackling the shortage of neurologists in the United States with cutting-edge technologies. By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool.
Between 2001 and 2016, the American Academy of Neurology (“AAN”) reported that out-of-pocket costs shot up substantially for privately insured patients. In addition, the distribution of neurologists across the U.S. is uneven, with patients in rural areas less likely to receive care (https://ibn.fm/9sUYR). There are 20 states, according to the 2017 Alzheimer’s Association International Conference, classified as neurology deserts (https://ibn.fm/cGx2k). This term designates an area that has projected a chronic shortage of neurologists alongside a rise in dementia cases.
“In many places, people do not have easy access to specialists, for a variety of reasons. But you may not need a neurologist in every case,” said Beth Kallmyer, MSW, vice president of Constituent Services at the Alzheimer’s Association. “With the right training and tools, primary care physicians can effectively diagnose and treat Alzheimer’s disease. The Alzheimer’s Association is working to arm primary care physicians with the tools they need to manage an increased caseload, as well as care planning guidance.”
Brain Scientific has developed tools that provide primary care physicians in neurology deserts the ability to serve their patients and create specialized treatment plans that provide access to neurologists. Portable, clinical-grade, easy-to-use diagnostic devices are now in place to allow to run EEG tests withing a few minutes. The company is actively working on a secure, cloud-based and highly scalable infrastructure to transmit patient data between neurologists and patients as well as creating artificial intelligence assisted diagnostic analysis.
Currently, across the United States, there is significant disparity between who has access to neurology care and who does not. A MedPate Today article reported that the lowest density had a mean of 9.7 neurologists for every 100,000 Medicare beneficiaries while the highest had 43.1 neurologists for every 100,000 (https://ibn.fm/dGCud). While the number of conditions remained similar, the access to care did not. With the explosion of telemedicine services and an increased integration of advanced practice providers, neurologists’ shortage may just improve.
Through portable EEGs, teleneurology, on-demand data exchange and AI predictive biomarkers, Brain Scientific will create resources to narrow this wide gap. The company’s commercialized products were designed to disrupt the slow, expensive and cumbersome EEG market with easy-to-use, economical and disposable solutions. These devices are so easy to use that any medical professional can use them within minutes in any setting to run routine EEG studies.
Brain Scientific can potentially change the United States’ landscape and eliminate neurology deserts once and for all. It’s time everyone had access to the life-saving research available.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, or FW-420 (“CRO”). The trial is designed to evaluate proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors (“ICIs”). This is the second clinical trial involving niclosamide that the CRO will manage for AzurRx. As previously announced, PPD is also managing AzurRx’s phase 2 clinical trial to investigate niclosamide as a treatment for COVID-19-related gastrointestinal infections; that trial is planned for Q2 2021. “The goal of our FW-420 clinical program is to develop a safe, effective, and non-systemic treatment for immune checkpoint inhibitor-associated colitis, and we are excited to once again partner with PPD to begin the preparations for our Phase 1b/2a clinical trial,” said AzurRx BioPharma president and CEO James Sapirstein in the press release. “The development of immune checkpoint inhibitors has marked a major advance in cancer therapeutics, but the drugs can induce a serious inflammation of the bowels, which if left unchecked, can prove life-threatening and force patients to halt treatment. There are currently no treatments available for grade 1 colitis resulting from the use of ICIs. We believe an oral, non-absorbed treatment, such as FW-420, could prevent the condition from progressing and enable patients to continue their treatment regimen uninterrupted. We hope to rapidly advance the FW-420 program with the support of PPD.”
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Nextech AR Solutions (CSE: NTAR) (NEO: NTAR) (FSE: N29) (OTCQB: NEXCF) has announced that it is partnering with Mash Media to deliver the first hybrid version of International Confex. Recognized as the United Kingdom’s largest and longest-standing show for event planners, International Confex is slated for June 22–23, 2021, at the ExCel Center in London. The event will be a hybrid blend of in-person and virtual activities. The two-day event, which features an agenda with more than 100 speakers and 60 seminars, is expected to draw more than 8,000 event professionals in person with another 5,000 attending online. Nextech will be an event sponsor and will also demonstrate its industry-leading, experiential engagement technologies including Augmented Reality (“AR”), Ad Network PromoteX and LiveX platform. Using NexTech’s technology, International Confex will streams the program on Nextech’s LiveX Digital Experience Platform (“DXP”), becoming the largest hybrid program for the event industry and expanding its reach and global attendance. Nextech will also enhance in-person and virtual attendee engagement throughout the event with its AR technologies that include holograms, digital-destination portals, 3D models, MapX and Ad Network. “We are excited to showcase our industry leading technologies at International Confex 2021 to build an impactful attendee experience,” said Nextech AR solutions CEO Evan Gappelberg in the press release. “Nextech AR is a tech company that puts AR into everything we do. Event planners, executives and thought leaders will be wowed by our DXP including AR holograms, 3D models, Digital Destination Portals and Ad Network.”
Nextech is one of the leaders in the rapidly growing augmented reality market estimated to grow from $10.7 billion in 2019 and projected to reach $72.7 billion by 2024 according to Markets & Markets Research; it is expected to grow at a CAGR of 46.6% from 2019 to 2024. The company is pursuing four verticals: Virtual Experience Platform (“VXP”), an advanced augmented reality and video learning experience platform for events; ARitize(TM) for eCommerce; ARitize 3D/AR advertising platform, the industry’s first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads; and ARitize Hollywood Studios, a project that produces immersive content using 360 video and augmented reality as the primary display platform. For more information about the company, please visit www.NextechAR.com
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at http://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Tuesday, April 13th, 2021UncategorizedComments Off on $NEXCF Will Be Official Digital Experience Platform for First Hybrid Edition of International Confex
Announces Participation in Upcoming Emerging Growth Conference
Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), will be presenting at the Emerging Growth Conference this week. VVOS CEO Kirk Huntsman, along with chief financial officer Brad Amman and investor relations officer Ed Loew, will host the presentation, which is scheduled for Wednesday, April 14, at 9 a.m. EDT. Interested investors can obtain a free spectator pass. In addition, a replay of the presentation will be available on the Vivos website.
Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Splash Beverage Group (OTCQB: SBEV), a holding company of a leading portfolio of beverage brands, today announced its entry into a partnership with Better Brands, a South Carolina distributor of more than 50 years that works with brands like Corona, Sam Adams, Danica Rose, Chateau Diana and more. According to the update, Better Brands will distribute SBEV’s SALT Naturally Flavored Tequila throughout the Myrtle Beach region, a world-renowned golfers’ paradise that attracts over 19 million visitors annually. Better Brands currently has 19 sales reps, six managers and two key account managers (“KAMS”) and is expanding the sales force for SBEV brands in line with increased opportunity and demand. “As COVID-19 restrictions continue to lift, we are growing our seasoned team of sales professionals to maximize potential across our portfolio of brands. Splash Beverage Group is primed for expedited growth like never before,” said SBEV CEO Robert Nistico. “Currently, we are evaluating a number of high-profile target acquisitions and will continue to add more brands and expand our extensive network of distributors nationwide.”
Splash Beverage Group specializes in manufacturing, distribution, sales and marketing of various beverages across multiple channels. SBEV operates in both the non-alcoholic and alcoholic beverage segments, which the company believes leverages efficiencies and dilutes risk. SBEV believes its business model is unique as it ONLY develops/accelerates brands it perceives to have highly visible preexisting brand awareness or pure category innovation. For more information about the company, visit www.SplashBeverageGroup.com.
NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at http://ibn.fm/SBEV
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
BOHEMIA, N.Y. , April 13, 2021 — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company”), a designer, developer, and manufacturer of custom and standard state-of-the-art RF components for Commercial, SATCOM, 5G, Quantum Computing, Space, Defense, and Military markets, announced today it received a developmental order from Amplify My Probe, Ltd, for a special cryogenic probe head used to facilitate the study of materials, molecules, and drugs for the treatment of diseases, among many other applications.
The probe uses AmpliTech’s innovative cryogenic low noise amplifier technology operating at 5 degrees Kelvin (-450 degrees F) physical temperature. These amplifiers have a uniquely low power dissipation and are also used in quantum computing, nanophysics, and astronomy applications.
Dr. Simenas Mantas, a designer on the Amplify My Probe, Ltd team that designed the EPR Cryoprobe stated, “The device allows the measurements of the Electron Paramagnetic Resonance (EPR) experiments to be done much faster by amplifying microwave signals and suppressing source noise. We anticipate close to 100x speedup of the experiments. Such an improvement is highly relevant in the field as it will significantly expand the domain of systems that can be studied by EPR. Among such systems are biomolecules, catalytic surfaces, materials for quantum computing and others.”
Among many other possible applications, the studying of such systems has the potential to speed up the design of new drugs (for example, to treat Alzheimer’s disease), increase efficiency of catalytic processes in chemical industry, and discover new materials for future quantum computers.
AmpliTech Group, Inc. will be the exclusive manufacturer for this product and Amplify My Probe will be its sole global distributor for a term of at least 18 months.
CEO Fawad Maqbool , stated, “We are pleased to work with the Amplify My Probe team to help develop this innovative new product that will advance materials science and medical technology. AmpliTech Group, Inc. is dedicated to be a driving force and leader in amplifier technology for communications and microwave applications that are part of everyday life around us.”
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, Defense and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz – eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented to us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers’ own designs. Website: http://www.AmpliTechinc.com .
About Amplify My Probe, Ltd.
Amplify My Probe is a spin out from the Quantum Spin Dynamics group at the London Centre for Nanotechnology and UCLQ. The Company is commercialising technology to improve the signal to noise ratio in EPR experiments. By placing low noise amplifiers in EPR probes, we collect and amplify signals before adding any thermal noise. Cooling the amplifiers cryogenically allows us to achieve noise factors much lower than room temperature operation. Our probes can be game changing for any EPR experiment with weak signals, where the experiment duration is determined by the need to average. https://www.amplifymyprobe.com/
This release contains statements that constitute forward-looking statements. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.
Tuesday, April 13th, 2021UncategorizedComments Off on $AMPG Receives Developmental Order for Cryogenic Device to Accelerate Design of New Drugs for Diseases and Materials for Quantum Computers
Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
XPhyto has just completed a rebranding effort that includes the launch of a new website
The company expects to begin launching other bacteria and virus diagnostic products later this year
With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response.
XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a Feb. 24 news release (https://ibn.fm/uBX94). The Covid-ID Lab is a rapid, point-of-care RT-PCR test system for COVID that the company expects to be useful for industry partners and licensees, as well as their respective government regulators, in safeguarding against the spread of the highly infectious and potentially fatal virus.
The first product order from 3a was for 9,600 tests, which are packaged in 200 kits of 48 tests each, according to the company. Delivery is expected this month and XPhyto anticipates they will then undergo evaluation by the company’s partners and the appropriate government agencies for expected commencement of sales in Q2 2021.
“We are pleased to report that all steps towards the launch of Covid-ID Lab remain on track within an ambitious timeline,” XPhyto CEO and Director Hugh Rogers stated in the news release. “Our experienced market launch team is working quickly to bring the product to market, as well as to establish licensing and distribution partnerships. We are confident that Covid-ID Lab, as a 25-minute PCR test with minimal technical and personnel requirements, will be a stand-out product in the COVID-19 test market.”
In March, XPhyto received two critical regulatory approvals in Europe to open the door for sales of its rapid, point-of-care COVID testing solution. On March 10, the company announced approval for commercial production under internationally agreed-on ISO 13485 quality standards (https://ibn.fm/qZCXm). On March 18, the company further announced Covid-ID Lab’s approval for in vitro diagnostic device (CE-IVD) use (https://ibn.fm/PqsZI).
On March 4, XPhyto announced completion of a corporate rebranding initiative that includes the launch of a new website.
“The company is excited to introduce a fresh look at such a pivotal point in our business growth,” Rogers added (https://ibn.fm/A4hzB).
XPhyto is on track to launch sales and distribution in Europe in April, and the company is also in talks with potential distribution and wholesale partners in the Middle East.
XPhyto intends to continue its rapid, point-of-care product development to target other pandemic-potential illnesses, such as H1N1 (swine flu) and H5N1 (avian flu), as well as a variety of other bacterial and viral infectious diseases. New products under an expanding portfolio could be launched before the end of the year.
XPhyto’s research and development operations are located in North America and Europe, but the company’s focus is the European market during these initial stages of product placement.
For more information on XPhyto Therapeutics, visit the company’s newly designed website at www.XPhyto.com.
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
LAS VEGAS and VANCOUVER, British Columbia, April 12, 2021 — TAAT ™ LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQX: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT ™ ”) is pleased to announce that on Thursday, April 15, 2021, TAAT™ Chief Executive Officer Setti Coscarella will be speaking at the Global Chinese Financial Forum (“GCFF”) Investing in Innovation virtual conference, delivering a presentation titled “Tobacco Disruptor” to a global audience, with approximately 300 attendees expected for each session at the conference. The presentation, which will feature translations for Chinese-speaking viewers, is scheduled to take place at 1:25 pm EDT / 10:25 am PDT for a duration of approximately 20 minutes. In this presentation, Mr. Coscarella will introduce TAAT™ and describe its unique position in the USD $814 billion global tobacco industry. Mr. Coscarella will highlight the Company’s progress to date, including the execution of the Company’s first U.S. product launch in Ohio, as well as bringing the TAAT™ e-commerce portal online to make the product available to the majority of smokers aged 21+ in the United States.
Thursday’s GCFF Investing in Innovation virtual event begins at 11:00 am EDT / 8:00 am PDT and will run until approximately 3:50 pm EDT / 12:50 pm PDT. Interested parties may register to attend at no charge on the event’s webpage: https://nai500.com/events/gcff-2021-investing-in-innovation/
The GCFF series is produced by NAI Interactive Ltd. (“NAI”), a market intelligence and investor relations service provider founded in 1998 with offices in Vancouver and Shanghai, with a focus on connecting North American public companies with Chinese investors. NAI has also gained reach in other Asian markets to include Taiwan, Singapore, and Hong Kong. In 2000, NAI began hosting investor events in global finance hotspots to include Toronto, Vancouver, Shanghai, and Shenzhen. The 20th GCFF Main Event was held in Toronto on November 2, 2019 before being adapted to a virtual event in 2020. Other recent GCFF events include Diversified Investing Strategies (November 5, 2020), Base Metals & Energy Metals Day (February 3, 2021), and Precious Metals Day (February 4, 2021).
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
TAAT™ CEO Setti Coscarella commented, “Now that we are establishing a presence in our initial market, we have a great story to share with a global audience of investors who may not yet be familiar with TAAT™ and its unique value proposition for smokers aged 21+. The concept of a smokable product with no tobacco or nicotine is very novel, and it has attracted considerable interest from investors in China, whose population of tobacco smokers is approximately eight times the size of Canada’s total population. It has been a pleasure to work with NAI to create a presentation for the GCFF Investing in Innovation event on Thursday, and I am looking forward to sharing our message with an eager and engaged audience of global investors as we continue to gain momentum with the launch of TAAT™ in the United States.”
On behalf of the Board of Directors of the Company,
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT ™ Lifestyle & Wellness Ltd.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion 1 global tobacco industry.
This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking information and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur, or be achieved. Forward-looking information in this news release includes statements regarding the potential launch of Beyond Tobacco™, in addition to the following: Potential outcomes from Setti Coscarella’s presentation of TAAT™ at the GCFF Investing in Innovation event on Thursday, April 15, 2021. The forward-looking information reflects management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking information. Although the Company believes that the assumptions and factors used in preparing the forward-looking information are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed timeframes or at all. Factors that could cause actual results or events to differ materially from current expectations include: (i) adverse market conditions; (ii) changes to the growth and size of the tobacco markets; and (iii) other factors beyond the control of the Company. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking information. The forward-looking information included in this news release are made as of the date of this news release and the Company expressly disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law.
The statements in this news release have not been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking the Company’s products will vary from person to person. No claims or guarantees can be made as to the effects of the Company’s products on an individual’s health and well-being. The Company’s products are not intended to diagnose, treat, cure, or prevent any disease.
This news release may contain trademarked names of third-party entities (or their respective offerings with trademarked names) typically in reference to (i) relationships had by the Company with such third-party entities as referred to in this release and/or (ii) client/vendor/service provider parties whose relationship with the Company is/are referred to in this release. All rights to such trademarks are reserved by their respective owners or licensees.
Disclosures relating to investor relations firms retained by TAAT™ Lifestyle & Wellness Ltd. can be found under the Company’s profile on http://sedar.com .
Monday, April 12th, 2021UncategorizedComments Off on $TOBAF CEO Setti Coscarella Delivering “Tobacco Disruptor” Presentation for Global Chinese Financial Forum Virtual Event on Thursday, April 15
PlantX Life Inc. (CSE: VEGA) (OTCQB: PLTXF) (Frankfurt: WNT1) today announced that it achieved record monthly gross revenue of $1,565,982 for March 2021 and a revenue of $1,353,613 for February 2021. As shown by recent financial results, PlantX continues to experience month-over-month revenue increases. The company’s new record gross revenue of $1,565,982 for the month of March 2021 reflects a 15.6% increase from February 2021 and a 43.7% increase from January 2021. These accomplishments build confidence on a continued growth trajectory and reflect the company’s dynamic expansion and unwavering commitment to deliver the best quality products and services to its loyal customer base. “The company’s progress is a manifestation of its results-driven strategy to capitalize on high-growth verticals, create strategic partnerships and expand globally,” said PlantX CEO, Julia Frank. “PlantX continues to add value as a leader in the plant-based industry.”
As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, the company currently has plans underway to expand its product lines to include cosmetics, clothing and its own water brand — but the business is not limited to an e-commerce platform. The company uses its digital platform to build a community of like-minded consumers and, most importantly, provide education. Its successful enterprise is being built and fortified on partnerships with top nutritionists, chefs and brands. The company eliminates the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit the company’s website at www.Investor.PlantX.com.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Some electric vehicle investors may rejoice after Ideanomics (NASDAQ:IDEX) posted its full-year 2020 results. The company posted strong numbers, including accelerating revenue. This lays the groundwork for IDEX stock upside in 2021 as the EV charging infrastructure expands.
Source: Videomatic/Shutterstock.com
Speculators may treat IDEX stock as a lotto pick, but in a few years the company’s industry disruption may pay off in two ways: Ideanomics Mobility and Ideanomics Capital.
Ideanomics Mobility will prosper from global EV market growth. It will do so by investing in the three pillars of EV enablement: vehicles, charging and energy.
Shared services within the Mobility unit will result in commercial fleet electrification. To increase its margins, IDEX has a strategy in finding synergy among its portfolio. For example, Treeletric, a subsidiary in Malaysia, received a purchase order from an Indonesian bike distributor. IDEX will fulfill the 10,000 unit service order.
IDEX’s Energica motorcycle investment introduces battery and charging technology to its portfolio. So, Treelectric may apply the battery and charging equipment in its product. This will drive revenue as early as the second half of the year.
A Closer Look at IDEX Stock
The charging and battery systems are central to the company’s Sales 2 Financing 2 Charging model. It serves three market segments through three brands: Medici Motor Works, Treeletric and Solectrac.
Ideanomics improves its products’ affordability by helping customers with financing. In the charging and energy services, IDEX sells WAVE wireless charging products. WAVE is the inductive charging business it bought in January.
Revenue from the acquisition may potentially accelerate this year. On the conference call, Chief Executive Officer Alfred Poor hinted that Antelope Valley Transit Authority is a potentially bigger customer in the quarters ahead.
IDEX China and Other Opportunities
Ideanomics acknowledged the under-performance in its China operations. Poor said recent management changes, including a new general manager for China, plus investing in the sales, business development and supply chain team should improve results.
“Our presence in China over the last few years has created deep knowledge of the logistics and supply chain requirements for the manufacturer of EVs, batteries, and related components,” Poor said.
Ideanomics appears to have more opportunities than the typical EV automotive company. For example, Energica is a 100% electric high-performance motorcycle; Solectrac is an EV targeting the underserved agriculture market. So, while EV cars and SUVs get crowded, Ideanomics is building a niche.
In the last fiscal year, IDEX accumulated $165.76 million in cash and cash equivalents. Revenue rose sharply, offset by the cost of revenue from third parties. Still, expenses for the year fell from $111.68 million to $88.63 million.
The company took a non-cash expense charge of $42.6 million in 2020, compared to $73.4 million. This move will improve the long-term value of the business.
In the table, the poor value score reflects the level of speculation in the share price.
Markets are betting on strong EV sales in the future. The stock’s price-to-sales ratio is 35.7 times. By comparison, the industry trades at below 10 times sales. The S&P 500’s price-to-sales is only 3 times.
IDEX shares may continue trading at high valuations so long as the market is willing to bet on a boom in the EV sector.
Sentiment may shift without notice. Once companies spend the government infrastructure grants, they may ask for more.
The U.S. government is in the early phases of supporting clean energy programs. Investors may gain exposure to the charging infrastructure expansion, battery-electric motorcycle market and EV in public transit (through Antelope Valley Transit Authority) by considering Ideanomics.
Disclosure: On the date of publication, Chris Lau did not have (either directly or indirectly) any positions in the securities mentioned in this article.
